LivaNova plc 2023 Q3 Form 10-Q Summary
Business Context and Reporting Period
LivaNova plc is a global medical technology company operating through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS) segments. This unaudited Form 10-Q covers the three and nine months ended September 30, 2023, with comparisons to the corresponding 2022 periods. Financial statements are presented in U.S. dollars under U.S. GAAP.
- Key products and programs include the Essenz Perfusion System, VNS Therapy, RECOVER clinical study, OSPREY clinical trial, LifeSPARC, and Hemolung.
- Essenz received U.S. FDA clearance and was commercially launched in the United States and broadly released in Europe during 2023.
- The Company began winding down its former heart failure program in the first quarter of 2023.
Financial Performance and Key Metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Net revenue | $286.1 million | $252.6 million | $843.4 million | $746.9 million |
| Revenue growth | 13.3% | — | 12.9% | — |
| Gross profit | $201.8 million | $170.9 million | $581.1 million | $523.7 million |
| Gross margin | 70.5% | 67.7% | 68.9% | 70.1% |
| Operating income (loss) | $4.5 million | $(132.0) million | $19.5 million | $(90.7) million |
| Operating margin | 1.6% | (52.2)% | 2.3% | (12.1)% |
| Net income (loss) | $(7.3) million | $(107.3) million | $1.2 million | $(87.9) million |
| Diluted EPS | $(0.14) | $(2.01) | $0.02 | $(1.64) |
| Net cash provided by operating activities | — | — | $21.0 million | $51.2 million |
- Cardiopulmonary revenue increased 19.7% in Q3 and 17.5% for the first nine months, driven by heart-lung machine placements, Essenz installations, and oxygenator demand.
- Neuromodulation revenue increased 5.8% in Q3 and 9.4% year to date, while segment income declined 3.1% and 18.9%, respectively, due primarily to contingent consideration remeasurement and higher clinical development costs.
- ACS revenue increased 26.8% in Q3 and 1.8% year to date. The ACS segment moved to $2.9 million of income in Q3 from a $134.9 million loss, and to an $8.3 million loss year to date from a $136.9 million loss, largely reflecting the absence of the $129.4 million ACS goodwill impairment recorded in 2022.
- Interest expense increased to $15.0 million in Q3 and $43.2 million for the first nine months, primarily because of higher interest rates and average borrowings.
- Foreign exchange and other income was $8.6 million in Q3 and $36.8 million year to date, compared with $38.5 million and $44.1 million, respectively, in 2022. Results included fair-value changes in exchangeable-note and capped-call derivatives and interest income.
Liquidity, Cash Flow, and Debt
- Cash and cash equivalents were $233.9 million at September 30, 2023, compared with $214.2 million at December 31, 2022.
- Restricted cash was $298.8 million, primarily collateral for the $270.0 million SNIA Litigation Guarantee. Consequently, total cash, cash equivalents, and restricted cash were $532.7 million.
- Working capital was $658.5 million, compared with $588.7 million at year-end 2022.
- Available short-term liquidity was $358.9 million, consisting of cash and $125.0 million of undrawn revolving-credit capacity. The $50.0 million Delayed Draw Term Facility was fully drawn in April 2023.
- Total debt obligations were $587.2 million, including $332.4 million of Term Facilities due July 2027 and $251.3 million of 3.00% cash exchangeable senior notes due December 2025.
- No borrowings were outstanding under the $125.0 million revolving credit facility, and the Company was in compliance with applicable financial covenants.
- Operating cash flow declined $30.3 million year over year to $21.0 million, primarily because of higher 3T Heater-Cooler litigation settlement payments and working-capital changes.
- Investing cash flow used $28.2 million, including $22.1 million of capital expenditures. Financing cash flow provided $26.5 million, including the $50.0 million Delayed Draw Term Facility borrowing.
Material Changes Versus the Prior Comparable Period
- The Company returned to positive operating income for both Q3 and the first nine months, compared with substantial operating losses in 2022.
- Net loss narrowed materially in Q3, and the Company reported modest year-to-date net income.
- The prior-year periods included a $129.4 million ACS goodwill impairment; no comparable impairment was recorded in 2023.
- Revenue growth was broad-based, led by Cardiopulmonary, while Neuromodulation remained the largest segment by revenue.
- Research and development expense increased to $46.5 million in Q3 and $147.7 million year to date, reflecting increased RECOVER and OSPREY activity and contingent consideration remeasurement.
- Inventories increased to $161.5 million from $129.4 million at year-end 2022, and the Company reported continuing supply-chain, labor, freight, and inflationary pressures.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide a clear quantitative revenue, earnings, or cash-flow guidance range. Management stated that current liquidity sources are expected to fund operating needs, working capital, capital expenditures, acquisition earn-outs, and debt service for the twelve months following issuance of the financial statements, subject to business and litigation risks.
- 3T Heater-Cooler litigation: the Company recorded $25.7 million of additional liability during the first nine months, with a provision of $29.7 million at September 30, 2023. Approximately 75 filed and unfiled claims were identified as of November 1, 2023; ultimate exposure may differ from the accrued amount.
- SNIA environmental litigation: an Italian Court of Appeal decision ordered approximately €453.6 million of damages and found potential liability up to an estimated €572.1 million. LivaNova appealed, and payment remains suspended subject to a €270.0 million bank guarantee supported by restricted cash. Further decisions were expected no earlier than 2024. No additional liability was recognized for this matter because the potential loss was not considered probable.
- Saluggia environmental obligations: the estimated liability was €36.0 million, or $38.1 million, at September 30, 2023, within an estimated range of €36.0 million to €45.8 million.
- Italian medical-device payback: the Company had reserved $7.6 million and obtained a suspension of regional payment requests pending litigation; actual liability could vary.
- Mitral litigation: Mitral asserted damages exceeding €20.8 million, while the Company indicated an applicable contractual cap of €8.0 million and accrued an immaterial amount.
- Macroeconomic risks include inflation, foreign-exchange volatility, geopolitical conflicts, sanctions, supply-chain disruptions, labor shortages, cybersecurity threats, reimbursement changes, product liability, regulatory approval, and clinical-trial risks.
- The UK’s implementation of the OECD Pillar Two framework may affect future tax rates beginning with accounting periods on or after December 31, 2023; the filing does not quantify the expected impact.
- Iran-related activity generated $0.4 million of revenue and $0.3 million of net profit in Q3, and $3.3 million of revenue and $1.4 million of net profit for the first nine months.
- Management concluded that disclosure controls and procedures were effective as of September 30, 2023, with no material changes to internal control over financial reporting.
Important Facts for Investors to Verify
- Progress and profitability of the Essenz commercial launch, including the effect of placements and related sales and marketing costs.
- Whether Neuromodulation revenue growth can offset higher RECOVER, OSPREY, and other development costs.
- ACS revenue trajectory and the extent to which the segment can reach sustained profitability without reliance on prior-year impairment comparisons.
- Cash conversion, inventory normalization, and operating cash flow after litigation payments and working-capital investment.
- Refinancing or repayment plans for the $251.3 million exchangeable notes due December 2025.
- Potential cash requirements related to 3T Heater-Cooler claims, SNIA litigation, Saluggia obligations, contingent consideration, and the Italian payback matter.
- Impact of higher interest rates, foreign-exchange movements, derivative fair-value volatility, and future tax-law changes.
- Timing and results of RECOVER and OSPREY clinical programs and any related CMS reimbursement developments.